Abstract
Objective To study the B-cell content, organization, and existence of distinct B-cell subpopulations in relation to the expression of type 1 interferon signature related genes in dermatomyositis (DM).
Methods Evaluation of skeletal muscle biopsies from patients with adult DM (aDM) and juvenile DM (jDM) by histology, immunohistochemistry, electron microscopy, and quantitative reverse-transcription PCR.
Results We defined 3 aDM subgroups—classic (containing occasional B cells without clusters), B-cell–rich, and follicle-like aDM—further elucidating IM B-lymphocyte maturation and immunity. The quantity of B cells and formation of ectopic lymphoid structures in a subset of patients with aDM were associated with a specific profile of cytokines and chemokines involved in lymphoid neogenesis. Levels of type 1 interferon signature related gene expression paralleled B-cell content and architectural organization and link B-cell immunity to the interferon type I signature.
Conclusion These data corroborate the important role of B cells in DM, highlighting the direct link between humoral mechanisms as key players in B-cell immunity and the role of type I interferon–related immunity.
Glossary
- aDM=
- adult dermatomyositis;
- CK=
- creatine kinase;
- DM=
- dermatomyositis;
- ELS=
- ectopic lymphoid structure;
- EM=
- electron microscopy;
- ENMC=
- European Neuromuscular Centre;
- HEV=
- high endothelial venule;
- IFN=
- interferon;
- jDM=
- juvenile dermatomyositis;
- MHC=
- major histocompatibility complex;
- mRNA=
- messenger RNA;
- MxA=
- myxovirus resistance gene A;
- qPCR=
- quantitative PCR;
- RIN=
- RNA integrity number;
- TRI=
- tubuloreticular inclusion;
- VAS=
- visual analog scale
Dermatomyositis (DM) is an idiopathic inflammatory disease of the skeletal muscle and skin, clinically characterized by symmetrical proximal muscle weakness and typical skin lesions. A clear distinction is made between juvenile DM (jDM) and adult DM (aDM) by (1) age—jDM onset is below the age of 16 years—and (2) distinct clinical presentation with, e.g., calcinosis cutis in jDM, rarely discovered in aDM,1 (3) possible association with cancer in aDM, which is absent in jDM, and (4) the occurrence of bowel vasculitis in jDM, which is rare in aDM. Furthermore, the involvement of molecular pathways of hypoxia and innate immunity has been found to be regulated differently in aDM and jDM.2 Beside genetic predispositions,3 the role of type I interferons (IFNs) has been identified as being prominently involved in DM.2,4 The treatment mainly relies on immunosuppressive and immunomodulatory agents, including CD20-targeting (B-cell depletion) strategies.5 Still, there are a significant number of nonresponders to immunosuppressive therapy (in aDM about 30%) limiting successful treatment options.6
Histomorphologically, perifascicular atrophy and specific injury to capillaries and perifascicular myofibers are pathognomonic in DM. The inflammatory infiltrate consists of dendritic cells, macrophages, CD4+ and CD8+ T cells, natural killer cells, plasmacytoid dendritic cells, and B cells, the significance of which is of utmost interest as potential and specific therapeutic targets.7,8 Nevertheless, the composition and regional distribution of the inflammatory cell infiltrates in skeletal muscle tissue vary conspicuously among patients with DM, ranging from sparse mixed infiltrates to nodular collections of highly organized B- and T-cell compartmentalization. These nodular collections may provide a permissive environment for clonal expansion and maturation of B cells in myositis muscle.8 We previously reported on the formation of ectopic lymphoid structures (ELSs) within the muscle tissue of patients with aDM.9 ELS formation has been described in other autoimmune diseases, e.g., MS, rheumatoid arthritis, and Sjögren syndrome,10,11 but seems to be very rare in adult and jDM.9,12 Nevertheless, the molecular mechanisms leading to formation of ELSs with germinal center–like reactions have not been fully elucidated.13 Therefore, we aim to further characterize the cytokine and chemokine milieu as well as the microarchitecture of aDM-associated B-cell infiltrates and ELSs. Based on these results, we discuss their functional and immunopathogenic implications.
Methods
Patient cohort
The available clinical and demographic information of all 23 patients enrolled in this study is listed in table e-1 (links.lww.com/NXI/A40). We included patients with typical symptoms of DM including characteristic livedoid skin rash/Gottron papules, proximal tetraparesis, muscle pain, and elevated creatine kinase (CK) levels. Furthermore, the ultrastructural presence of tubuloreticular inclusions (TRIs) in endothelial cells, the presence/absence of autoantibodies, including anti-Jo1, -Mi2, -SRP, -PL7, -PL12, anti-Ro52, or -KU, serum CK, and the clinical outcomes were documented. Anti-Mi2 autoantibody-positive patients were included in the DM group, whereas patients with antisynthetase autoantibodies or necrotizing myopathy and anti-SRP autoantibodies were excluded. Patients with aDM were selected based on the presence or absence of B-cell infiltrates and ELSs. Patients with jDM had classic DM morphology without significant numbers of B cells or ELSs.
Standard protocol approvals, registrations, and patient consents
Informed consent was obtained from all patients at each institution involved. Ethical approval (EA1/204/11) was granted by the Charité Ethics Committee.
Skeletal muscle specimens
We analyzed skeletal muscle biopsies from patients diagnosed with aDM (n = 16), according to the clinico-morphological European Neuromuscular Centre (ENMC) criteria,14 and jDM (n = 4), according to the ENMC and international consensus criteria for the severity of jDM disease.15 In addition, we investigated control skeletal muscle biopsies (n = 3) from patients with nonspecific complaints in a context of “fatigue-like” symptoms, but without clinical muscle weakness, absence of morphologic abnormalities on skeletal muscle biopsy, or elevated CK levels, or laboratory evidence of any systemic inflammation. We have previously shown that there were no differences in gene expression levels of adult and juvenile controls.2 The muscle specimens were cryopreserved at −80°C for routine diagnostic workup or preserved in glutaraldehyde for ultrastructural analysis. All DM samples were evaluated according to an adapted visual analog scale (VAS), which was originally introduced for jDM.15 In analogy to the original VAS, we assessed the muscle involvement of all 4 compartments/domains (inflammatory, vascular, muscular, and connective tissue) separately. Special stains used to evaluate each domain included the following: CD3, CD45, CD68 (inflammatory), CD31 (vascular), major histocompatibility complex (MHC) class I (muscular), and Elastica van Gieson (connective tissue). The global impression of each domain was scored on a 0-10-point scale to illustrate the association of DM subgroups and domain-specific muscle involvement. VAS scoring was performed by J.R. and W.S. in a blinded fashion for all samples. DM samples were further analyzed based on the presence of specialized B-cell subpopulations and B- and T-cell compartmentalization (organized separation of specialized T and B cells). Three histologic aDM subgroups were defined: classic aDM (n = 6), B-cell–rich aDM (n = 7), and follicle-like aDM (n = 3), the latter required the presence of ectopic germinal center formation.
Histologic, enzyme histochemical, immunohistochemical, and immunofluorescence procedures
Routine stains were performed on 7-μm cryostat sections according to standard procedures. Immunohistochemical, double immunofluorescence stains and electron microscopy (EM) were performed as described previously.2,16 Primary antibodies are listed in table e-2 (links.lww.com/NXI/A40).
RNA extraction
Total RNA was extracted from muscle specimens using the mirVana miRNA Isolation Kit (Life Technologies, Darmstadt, Germany) according to the manufacturer's instructions. The RNA integrity number (RIN) was determined using an Agilent 2100 Bioanalyser (Agilent Technologies, Santa Clara, CA). The RNA 6000 Nano LabChip Kit (Agilent Technologies) was used to analyze the degradation level. All 23 samples fulfilled the RNA quality criteria (RIN > 8).
Quantitative reverse-transcription PCR
Complementary DNA was synthesized using an RT2 First Strand Kit (Qiagen, Hilden, Germany). Real-time PCR was performed using a custom RT2 profiler quantitative PCR (qPCR) assay (Qiagen). Glyceraldehyde 3-phosphate dehydrogenase was included in the custom-made qPCR assay as an internal control to normalize the expression of the target genes. The qPCR assay identification numbers are listed in table e-3 (links.lww.com/NXI/A40). A summary table of the qPCR results can be found in the supplementary material (table e-4).
Statistical analysis
Kruskal-Wallis one-way analysis of variance followed by Bonferroni-Dunn correction of the post hoc tests was used to analyze quantitative differences of messenger RNA (mRNA) transcripts and the VAS score. Data are presented as mean ± SEM. The level of significance was set at p < 0.05. GraphPad Prism 5.02 software (GraphPad Software, Inc., La Jolla, CA) was used for statistical analysis.
Results
Morphological analysis
We performed histopathologic evaluation of serial sections of muscle samples (figure 1) based on 4 different domains (inflammatory, vascular, muscle fiber, and connective tissue; figure 2). DM samples were further classified based on the location, organization, and architecture of the inflammatory infiltrate.
Classic aDM (A, B) with characteristic perifascicular atrophy. B-cell–rich (C, D) and follicle-like aDM (E, F) with dense lymphocytic aggregates and jDM (G, H) with demarcated infarction of small muscle fascicles with focal loss of normal microarchitecture (scattered line). Internalized myonuclei (B, F, arrowheads), myophagocytosis (D, arrowhead), and the presence of nonrimmed vacuoles (G, arrowhead) were seen in all muscle specimens but were more often detected in B-cell–rich and follicle-like aDM and in jDM. aDM = adult dermatomyositis; jDM = juvenile dermatomyositis.
Muscle specimens were evaluated based on 4 domains (inflammatory [INFL], vascular [VASC], muscle fiber [MF], and connective tissue [CT]). In jDM and classic aDM, CD68+ macrophages were diffusely distributed in the perimysium and adjacent endomysium (A, arrowheads; D). In B-cell–rich and follicle-like aDM, CD68+ macrophages were predominantly seen in the periphery of the lymphocytic aggregates (B, C, arrowheads). Expression of MHC class I molecules was predominantly seen in the perifascicular region of jDM and classic aDM muscle samples (2 patients: Ea and Eb, arrowheads; H, arrowheads) and in B-cell–rich and follicle-like aDM on the sarcolemma of all muscle fibers with perifascicular enhancement (F, G). CD31 highlighted the capillary loss, which was most prominent in the perifascicular region in jDM (L, arrows) and milder in classic (I, arrows), B-cell–rich, and follicle-like aDM (J, K). Elastica van Gieson (EvG) staining was used to evaluate IM fibrosis (M–P), which was more prominent in B-cell–rich (N) and follicle-like aDM (O) than in jDM (P) and classic aDM (M). (Q) Results of the evaluation of the adapted VAS score (higher scores = more disease activity). (R, S) mRNA expression of chemokines CCL2,-13,-17,-19,-21 and chemokine receptors CXCR3,-4,-5 in different DM subgroups was measured by real-time PCR (RT-PCR). The ΔCT of healthy controls was subtracted from the ΔCT of patients with DM to determine the differences (ΔΔCT) and fold change (2^−ΔΔCT) of gene expression. Gene expression was illustrated by the log10 of fold change values compared with the normal controls. Results show mean ± SEM. *p < 0.05, **p < 0.01. aDM = adult dermatomyositis; DM = dermatomyositis; IM = intramuscular; jDM = juvenile dermatomyositis; mRNA = messenger RNA.
Inflammatory domain
To further characterize the inflammatory infiltrate in all DM subgroups, we performed various immunohistochemical stains. In skeletal muscle biopsies of patients with jDM and classic aDM, the inflammatory infiltrate was diffusely distributed and mainly located in the perimysium and partly in the adjacent endomysium (figure 1, A, B, G, and H). It consisted of CD45+ lymphocytes (data not shown), CD68+ macrophages (figure 2, A and D), CD3+ T-lymphocytes (data not shown), and only few CD20+ B-lymphocytes (figures 3, A and D). By contrast, samples of B-cell–rich and follicle-like aDM muscle biopsies demonstrated significantly more inflammatory infiltrates, which were located in both the perimysium and endomysium (figure 1, C–F), consisting of many CD20+ B-lymphocytes (figure 3, B and C). B-cell–rich aDM samples showed dense CD20+ B-cell aggregates, lacking T-B compartmentalization (figures 1, C and D, 3B). Muscle specimens of follicle-like aDM demonstrated follicle-like structures, resembling tertiary lymphoid organs with germinal centers and dark and light zone organization (figure 1, E and F).
Muscle sections were stained with CD20 to highlight the B-cell content in different DM subgroups (A–D, arrowheads). ELSs showed clear compartmentalization of peripheral CD3+ T cells (E) and CD21+ (F) B cells. The germinal center–like structures consisted of D2-40+ follicular dendritic cells (FDCs) (G), CD23+ B cells (H), MUM1+ B cells (J), and CD31+ HEVs (K) with PAX5+ B cells mainly distributed around them (L). Increased proliferative activity in the B-cell–rich germinal center–like area was indicated by Ki67/MIB1 immunostaining (M). Immunofluorescent labeling demonstrated partial colocalization of central CD20+ B cells with POU2AF1 (BOB-1) (N). (I) mRNA expression of PAX5 and POU2AF1 measured by real-time RT-PCR. The reciprocal ΔCT values are displayed to illustrate levels of gene expression of PAX5 and POU2AF1, genes whose expression was not detectable in ≥2 healthy controls. Results show mean ± SEM. *p < 0.05, **p < 0.01. DM = dermatomyositis; ELS = ectopic lymphoid structure; mRNA = messenger RNA; RT-PCR = real-time PCR.
Vascular domain
Previous studies have suggested that the mean ratio of capillaries to muscle fibers in healthy muscle tissue is usually 1.0.17 We performed immunohistochemical stains for CD31 to evaluate the capillary density/the capillary-to-fiber ratio in all muscle samples (figure 2, I–L). Capillary loss was most prominent in jDM (figure 2, L and Q) and milder in B-cell–rich (figure 2, J and Q), follicle-like (figure 2, K and Q), and classic aDM (figure 2, I and Q), in the latter, like in jDM, predominantly affecting the perifascicular region (figure 2, I and L; inserts). Demarcated infarction of small groups of fibers in muscle fascicles with focal loss of normal cytoarchitecture was present exclusively in 2 jDM muscle specimens (figure 1H, scattered line).
Muscle fiber domain
All muscle biopsies revealed upregulation of MHC class I (figure 2) and partially of MHC class II (data not shown) molecules on the muscle fiber surface. In jDM and classic aDM, expression of MHC class I molecules was seen predominant in the perifascicular region (2 patients: figure 2, Ea, Eb, and H [arrowheads]), in B-cell–rich and follicle-like aDM on the sarcolemma of all muscle fibers with perifascicular enhancement (figure 2, F and G). Of interest, perifascicular atrophy was most prominent in jDM (figure 1, G and H) and classic aDM (figure 1, A and B) and less pronounced in B-cell–rich (figure 1, C and D) and follicle-like aDM (figure 1, E and F).
Connective tissue domain
Increased perimysial and endomysial connective tissue was seen in all muscle samples (figure 2, M–P), but was generally more pronounced in samples with extensive inflammatory infiltration (B-cell–rich and follicle-like aDM; figure 2, N, O, and Q). However, perimysial fragmentation of connective tissue or alkaline phosphatase activity was absent in all specimens.
Role of type 1 IFN cytokines in different aDM subtypes
We studied a comprehensive panel of genes encoding cytokine and adhesion factors, associated with, e.g., innate and adaptive immunity, inflammatory response, apoptosis, B-cell homeostasis, and germinal center formation of which many play an essential part in regulating type I IFN-induced activation and interferon-stimulated gene (ISG) transcription and translation. We detected very high expression levels of STAT3 (figure e-1A, links.lww.com/NXI/A40) and IFN-stimulated exonuclease gene 20 kDa (ISG20) in all DM subgroups (figure e-1B). ISG20 staining was in fact strong on the sarcoplasm of perifascicular fibers in jDM and classic aDM (figure 4D, arrowheads) and more diffuse in B-cell–rich and follicle-like aDM. Overexpression of myxovirus resistance gene A (MxA)—marker for ISG induction and IFN response18,19—was detected in the perifascicular region of all cases, but was—in contrast to ISG20 (figure 4D, arrows)—additionally strongly expressed by B cells in B-cell–rich and follicle-like aDM (figure 4C, arrowheads). MxA staining was also found on capillary walls (figure 4C, arrows) linking this molecule to development of TRIs in endothelial cells and interestingly in B cells (figure 4B, arrowheads), which are held to be a consequence of increased IFN expression.16,20 We further detected that many of the type 1 IFN-inducible genes—identified using INTERFEROME v2.0121—were highly upregulated in muscle samples with high B-cell content (B-cell–rich and follicle-like aDM). In fact, CCL19 (figure 2R), CXCR4 (figure 2S) CXCL12, CXCL13 (figure 4A), CCR7 (figure e-1C), IL7, and IL23A (figure e-1D) were significantly upregulated in B-cell–rich and follicle-like aDM compared with classic aDM and jDM, with highest expression of CCL19, CXCL12, CXCR4, and IL7 in follicle-like aDM.
CD23+ B cells are a source of CXCL13 as indicated by double immunofluorescent staining (A, arrowheads). Gene expression of CXCL12 and CXCL13 was illustrated by the log10 of fold change values compared with the normal controls. Results show mean ± SEM. *p < 0.05, **p < 0.01. (B) EM revealed tubuloreticular inclusions (arrowheads) in the cytoplasm of a B-lymphocyte (solid and dashed boxes indicate magnified areas; * = mitochondrion). MxA staining revealed strong expression in the perifascicular area on myofibers and capillaries (C, arrows) in all cases and additional expression by B cells in B-cell–rich and follicle-like aDM (C, arrowheads). In contrast to healthy controls, muscle fibers of different DM subgroups showed upregulation of ISG20 (D; CRTL: normal control). aDM = adult dermatomyositis; DM = dermatomyositis; IFN = interferon; IM = intramuscular; ISG = interferon-stimulated gene; MxA = myxovirus resistance gene A; n = nucleus.
Th1- and Th17-mediated immunity is associated with B-cell aggregates in aDM
Previous studies brought attention to the role of different T-cell subsets in ectopic lymphoneogenesis and germinal center–like formation. Th1-mediated immunity in general is known to be specifically involved in the immunopathogenesis of DM. Of interest, cytokines linked to Th17 and Th1 immunity were significantly associated with B-cell aggregation and ELS formation in our study. In fact, Th17-associated cytokines IL7, IL12A, IL23A, and CCR622,–,24 were all significantly upregulated in B-cell–rich and follicle-like aDM (figure 1, C and D), with highest expression of IL7 and CCR6 in follicle-like aDM. This was further supported by strong expression of Th1-specific CXCR325 (figure 2S), TNFA (figure e-1G, links.lww.com/NXI/A40), and INFγ (data not shown) in follicle-like aDM, suggesting that ELS formation in DM muscle tissue is strongly influenced by Th1 and Th17 lineages.
Morphologic and molecular analyses of B-cell infiltration, maturation, and ELS formation in DM
To further characterize ectopic lymphoid follicle–like structures, we performed additional immunohistological stains and quantitative reverse-transcription PCR analysis of genes associated with lymphoid neogenesis and B-cell maturation. The center of the lymphoid follicle–like structures, mainly composed of CD20+ B cells (figure 3C), was surrounded by a CD3+ T-cell–rich periphery (figure 3E). High endothelial venules (HEVs; figure 3K) and D2-40+ follicular dendritic cells (figure 3G) were only seen in follicle-like aDM, but not in samples of other subgroups (data not shown). Cytokines involved in lymphoid neogenesis such as CXCR5, CCL19, CCL21, CXCL12, CXCL13, LTA, LTB, and TNFSF13B were—with the exception of CXCR5 and LTA—highly expressed in all DM subgroups in comparison with healthy controls (figure 2, R and S; figures e-1F and G, links.lww.com/NXI/A40). However, highest expression of these molecules was found in follicle-like aDM. Double immunofluorescence staining suggested that not only follicular dendritic cells but also CD23+ B cells seem to be a source of CXCL13 within these ectopic lymphoid follicle–like structures (figure 4A, arrowheads). We further investigated the differentiation state of infiltrating B cells and the mRNA and protein expression of POU2AF1 (BOB1), IRF4 (MUM1), PAX5, and PRDM1, genes/proteins involved in different functional or maturational B-cell subsets, e.g., within the germinal center.26,–,29 Specialized mature follicular CD21+ and CD23+ germinal center B cells (figure 3, F and H) were only detected within ELSs of follicle-like aDM, but not in other DM subgroups (data not shown). POU2AF1, IRF4, PAX5, and PRDM1 were highly upregulated in follicle-like aDM, slightly less expressed in B-cell–rich aDM, and showed significantly lower mRNA levels in classic aDM and jDM (figure 3I, figure e-1E). In follicle-like aDM, many POU2AF1+ (BOB1+, figure 3N, figure e-1H, arrowheads), PAX5+ (figure 3L), and MUM1+ (figure 3J) B cells were found in the center of the ELSs with few CD138+ plasma cells seen in the periphery (figure e-1I, arrowheads). Figure 3N demonstrates the colocalization of POU2AF1 and CD20 in the follicle-like structures. POU2AF1+ and PAX5+ B cells were scarce in B-cell–rich aDM and absent in classic aDM or jDM (data not shown).
Discussion
Ectopic lymphoid neogenesis can occasionally be recognized in nonlymphoid tissues in different autoimmune and chronic inflammatory diseases such as rheumatoid arthritis, Sjögren syndrome, MS, Hashimoto thyroiditis, Helicobacter pylori–induced gastritis, and chronic hepatitis C virus infection.10,13,30 However, in DM, ELS formation with germinal center architecture seems to be an extremely rare phenomenon, which is very likely regulated by specific immune-inflammatory mechanisms. Therefore, our study further aimed at elucidating the impact of B cells on the pathogenesis of DM using the follicle-like variant as a paradigm.
To characterize different histologic DM subgroups in terms of B-cell composition, skeletal muscle tissue of patients with DM was graded histologically and immunohistochemically for the presence and number of B cells, follicle-like aggregates, and the presence of ectopic germinal centers. We further evaluated the molecular signature of type 1 IFN-driven genes, known to be intimately involved in the pathogenesis of DM,2,4,19,31 as well as genes implicated in lymphoangiogenesis. Consistent with the presence of dense B-cell aggregates, high expression of CXCL12, CXCL13, CCL19, LTA, LTB, CXCR4, CXCR5, CCR7, and IL23—genes known to induce lymphoneogenesis—was found at sites of chronic inflammation. These cytokines have all also been reported to be pivotal for B-cell migration.23,32,33 They were associated with increasing size of B-cell aggregates and formation of ELSs with compartimentalization of B- and T-cell zones, HEVs, and D2-40+ follicular dendritic cell networks. We further show that not only follicular dendritic cells but also CD23+ B cells as specialized mature B-cell subpopulations seem to be a source of CXCL13 expression within ELSs in aDM, suggesting a positive feedback mechanism that contributes to the recruitment of additional cells.34
Both TNFSF11 (RANKL) and TNFSF13B (BAFF) have been identified to play a role in several autoimmune diseases and are reported to be intimately involved in the development of ELSs in rheumatoid arthritis and Sjögren syndrome.35,–,37 Moreover, RANKL-deficient mice demonstrate profound defects in lymph node formation and B-cell development, which highlights its significance in lymph node organogenesis.38 Accordingly, we identified a significant increase of TNFSF11 and TNFSF13B expression in follicle-like aDM muscle samples, providing support that both are also associated with ELS formation in aDM.
The formation of ectopic germinal centers with B-cell proliferation and different states of B-cell maturation is further highlighted by PAX5, IRF4 (MUM-1), and PRDM1 expressed by maturing B cells. These genes and proteins, involved in the terminal differentiation along plasma cells lineage,28,39 were highly expressed by proliferating B cells within the center of ELSs in follicle-like aDM.
Of note, we observed a significant upregulation of numerous genes implicated in different aspects of the IFN signature in B-cell–rich and follicle-like aDM muscle tissue in contrast to classic aDM and jDM. Although not selectively induced by type I IFN, previous studies provided evidence that most of these IFN-stimulated genes can be considered type I IFN-driven in the context of DM.4,40 In fact, we have investigated a large panel of genes representative for the type 1 IFN signature, e.g., MxA, ISG20, CCL19, CXCL12, CXCR4, and IL72,19,21 and others, reported to orchestrate T-cell responses, apoptosis, and adaptive immunity and found that they were all involved in DM, significantly correlating with the intrinsic amount of B cells. In fact, especially MxA staining revealed most striking staining results in B-cell–rich and follicle-like aDM, illustrating that not only the ISGs are involved in numerous relevant pathomechanisms in DM but also highlights that therapies targeting type 1 IFNs may act effectively on multiple levels of the immune response.
In addition, we present that B-cell aggregates in aDM samples are associated with significant upregulation of cytokines involved in Th1- and Th17-mediated immunity, e.g., CXCR3,25 and TNFA.
We, therefore, hypothesize that the prominent in situ B-cell differentiation in skeletal muscle during DM may dysregulate (adaptive) immunity leading to excessive IFN response, which itself may fuel an amplification loop (figure 5) that enhances adverse pathomechanisms in DM. Our results suggest that these pathomechanisms seem to occur independent of the presence of ectopic germinal center formation, in both B-cell–rich and follicle-like aDM, which might, therefore, be considered to belong to the same clinicopathologic spectrum. Assessment of B-cell architecture, including ultrastructure and function, together with ISG analysis can be useful tools to stratify patients with DM and develop therapies targeting, e.g., B-cell immunity or type 1 IFN signaling for these disease subsets individually. Nevertheless, further prospective clinical studies will be needed to determine the effectiveness of such therapeutic options in the context of DM.
Skeletal muscle in DM shows perifascicular atrophy and loss of capillaries. Both myofibers and capillary endothelial cells express type 1 IFN-inducible gene transcripts. In addition, B cells within the endo- and perimysial space express type 1 IFN-inducible gene transcripts, e.g., MxA. Tubuloreticular inclusions within endothelial cells and B cells can be considered downstream markers of type 1 IFN signaling, illustrating specific damage of these structures. The reciprocal effects of IFNs on the perifascicular fibers, capillaries, and B cells may, once activated, feed an amplification loop that enhances adverse pathomechanisms in DM. DM = dermatomyositis; IFN = interferon; MxA = myxovirus resistance gene A.
Author affiliation
From Charité—Universitätsmedizin Berlin (J.R., R.K., C.P., D.P., K.T., C.S., F.L.H., H.-H.G., W.S.); Corporate Member of Freie Universität Berlin (J.R., R.K., C.P., D.P., K.T., C.S., F.L.H., H.-H.G., W.S.); Humboldt-Universität zu Berlin (J.R., R.K., C.P., D.P., K.T., C.S., F.L.H., H.H.G., W.S.); Department of Neuropathology (J.R., R.K., C.P., D.P., K.T., C.S., F.L.H., H.-H.G., W.S.), Berlin Institute of Health; German Consortium for Translational Cancer Research (DKTK) (J.R., R.K., F.L.H.), Partner site Charité Berlin; ZTB Zentrum für Transfusionsmedizin und Zelltherapie Berlin (K.T., C.S.), HLA Tissue Typing Laboratory; Department of Neuropathology (J.W.), Uniklinik RWTH Aachen; Department of Neuropathology (S.D.), Universitätsklinikum Freiburg; Berlin Institute of Health (BIH) (J.R., F.L.H.); Leibniz Science Campus Chronic Inflammation (F.L.H., W.S.), Berlin, Germany; Assistance Public-Hôpitaux de Paris (Y.A., O.B.), Université Pierre et Marie Curie, UMR974; Department of Internal Medicine and Clinical Immunology (Y.A., O.B.), and Department of Clinical Neurophysiology (T.M.), Pitié-Salpêtrière University Hospital, France; and Department of (Neuro)Pathology (E.A.), and Department of Neurology and Neurophysiology (M.d.V.), Academic Medical Centre, University of Amsterdam, the Netherlands.
Author contributions
J. Radke, W. Stenzel, and H.H. Goebel: study concept and design, acquisition analysis, and interpretation of data. R. Koll, C. Preuße, D. Pehl, K. Todorova, C. Schönemann, Y. Allenbach, E. Aronica, M. de Visser, J. Weis, S. Doostkam, F.L. Heppner, T. Maisonobe, and O. Benveniste: acquisition, analysis, and interpretation of data.
Study funding
Deutsche Gesellschaft für Muskelkranke e.V. (DGM) to J.R.
Disclosure
J. Radke received research support from Deutsche Gesellschaft für Muskelkranke. R. Koll and C. Preuße report no disclosures. D. Pehl received research support from Deutsche Gesellschaft für Muskelkranke. K. Todorova, C. Schönemann, Y. Allenbach, and E. Aronica report no disclosures. M. de Visser is on the editorial board of Neuromuscular Disorders, Clinical Neurology, and Neurosurgery and is a member of the adjudication committee of Bristol-Myers Squibb. F.L. Heppner has a patent application for Modulators of Il-12 and/or IL-23 for the prevention or treatment of Alzheimer's disease and is a founding scientist of Myosotis Therapeutics AG, which has licensing rights from the University of Zurich and the Charité—Universitätsmedizin Berlin on the Use of modulators of IL-12 and/or IL-23 for the prevention or treatment of Alzheimer's disease. J. Weis received travel funding and speaker honoraria from Ultragenyx; received royalties from Wiley-Blackwell; and received research support from the German Research Foundation, German Ministry of Science and Education, EU Joint Program Neurodegenerative Disease Research, JARA-BRAIN, Initiative Therapieforschung ALS e.v., and German Society for Muscle Diseases. S. Doostkam and T. Maisonobe report no disclosures. O. Benveniste served on the scientific advisory board of CSL Behring, Novartis, and LFB; received funding travel from CSL Behring and LFB; consulted for Novartis and CSL Behring; and received research support from LFB, Novartis, Shite, CSL Behring, DGOS/INSERM, PHRC, AFM, and The Myositis Association. H.H. Goebel served on the editorial board of Neuromuscular Disorders, Neuropathology and Applied Neurobiology, Brain Pathology, and Clinical Neuropathology. W. Stenzel served on the editorial board of Neuromuscular Disorders, Neuropathology, and Applied Neurobiology. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/NN.
Acknowledgment
The authors thank Hanna Plückhan, Cordula zum Bruch, and Petra Matylewski for excellent technical assistance and Yanick Crow for fruitful scientific discussion on IFN signaling in dermatomyositis. JR is a participant in the BIH-Charité Clinical Scientist Program funded by the Charité—Universitätsmedizin Berlin and the Berlin Institute of Health. This work was supported by the Leibniz ScienceCampus Chronic Inflammation (chronische-entzuendung.org).
Footnotes
Funding information and disclosures are provided at the end of the article. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/NN.
- Received December 1, 2017.
- Accepted in final form February 2, 2018.
- Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
References
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
